Skip to content

Curative Proton Beam Therapy for Patients With Liver Metastasis of Colorectal Cancer

A Phase II Study of Curative Proton Beam Therapy for Patients With Liver Metastasis of Colorectal Cancer

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03577665
Enrollment
30
Registered
2018-07-05
Start date
2018-05-21
Completion date
2025-12-31
Last updated
2019-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

Liver Metastasis, Curative Proton Beam Therapy

Brief summary

Proton alone therapy is performed -\> 5 times a week, 7200 cGy / 15 fractions for 3 weeks total

Detailed description

This clinical trial is a prospective, single-organ, phase II clinical trial to evaluate the efficacy of curative proton therapy for liver metastasis of colorectal cancer diagnosed histologically as adenocarcinoma. Patients who meet the selection criteria should be selected, signed for consent, and treated 5 times a week for 7200 cGy / 15 fractions alone for 3 weeks.

Interventions

Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks

Sponsors

National Cancer Center, Korea
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Histologically diagnosed colon adenocarcinoma in primary or metastatic lesions.. 2. If there is no other remote metastasis other than liver, or if there is, control is possible 3. If there are less than 2 liver metastatic lesions 4. If they refuse lung surgery or surgery is inappropriate (medically unsuitable for surgery due to surgery refusal, diabetes mellitus, high blood pressure, pulmonary disease, heart disease, etc., repeated surgery, poor systematic function, short disease-free period, etc.)

Exclusion criteria

1. Other histologic cancer other than adenocarcinoma of the colorectal 2. Colorectal cancer without primary lesion resection 3. If there is another remote metastasis and is not completely resected or regulated 4. If the patient has experience of other invasive cancer diagnosis within 5 years of colorectal cancer diagnosis 5. Pregnancy and women under lactation

Design outcomes

Primary

MeasureTime frameDescription
2-year local control ratio of the treated liver areaTime Frame: up to 2 yearsThe primary goal of this study is the 2-year local control rate of liver lesions treated with proton therapy. It is judged that the local control rate is improved when the liver metastases of colorectal cancer using conventional X-ray is assumed to have 2-year local control rate of 60% and the 2-year local control rate of proton therapy is set to 80% or more

Secondary

MeasureTime frameDescription
5-year survival rate of treated patientsdocumented data of death, up to 5 years.To evaluate whether high doses of proton therapy can replace conventional surgical resection. From date of initiation of proton therapy until the date of documented date of death from any cause, assessed up to 5 years
5-year disease-free survival rate of treated patientsdocumented date of progression or death, up to 5 yearsTo evaluate whether high doses of proton therapy can replace conventional surgical resection. From date of initiation of proton therapy until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.

Countries

South Korea

Contacts

Primary ContactDae Yong Kim, M.D.
radiopia@ncc.re.kr+82-31-920-1721

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026